DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c12440) has announced the addition of Business Development and R&D Database: Oncology in Big Pharma to their offering
This unique CD-ROM database was compiled to enable your independent and unbiased analysis. By using this database you will be able to gain knowledge about the progress made by the large pharmaceutical companies in the field of oncology. This database provides more than 10 000 records carefully identified and defined in several subcategories (see below). All records included are associated to cancer therapeutic projects related to the large pharmaceutical industry.
This exclusive database provides you with an update on the most recent advances made as well as a historical view demonstrating the competitive struggle that exists between the large pharmaceutical companies. The searchable database will also provide information about pitfalls as well as competition and business opportunities in the oncology field.
The information in the database has carefully been selected and structured to provide the most optimal and time saving platform to work from, if you are interested in general descriptions on drugs and targets as well as B2B collaborations, industry academic relationships and patent information.
Generally, the database is structured into four sections:
- R&D activities
- Company profiles
The R&D information is structured into 11 searchable segments:
- Drug name
- Combinatory drugs
- Developmental stage
- Therapy given
- Drug Effects
- General comments
- Source of data
The collaboration information is structured into 5 searchable segments:
- Developmental stage
- Type of collaboration
- Type of terms
This broad database will enable you to track down the most competitive up coming oncology drugs in a near future as well as identifying the hottest collaborations. Identify and structure most B2B collaborations and industry-academic alliances.
Some of the drugs included in the database:
Alimta, Aromasin, Avastin, Bay 43-9006, BMS-247550, CCI-779, Edotecarin, Erbitux, Faslodex, Gleevec, Herceptin, IMC-BEC2, Iressa, Lapatinib, MelVax, PTK787, Sarasar, SU011248, Tarceva, Thalomid (+thalidomide analogs) Tirapazamine and Xeloda.
Some of the companies included in the database:
Eli Lilly, Pfizer, Genentech, Bayer AG, Bristol Myers-Squibb, Wyeth, AstraZeneca, F Hoffmann-La Roche, Merck KGaA, GlaxoSmithKline and Schering-Plough
For more information visit http://www.researchandmarkets.com/reports/c12440
COPYRIGHT 2005 Business Wire
COPYRIGHT 2005 Gale Group